Loading...
Back
BPHY
BIOPHYTIS SA
()
2024 6-K
Follow
Summary
Share
Summary
Financial Statement Delay
30 Apr '26
Participation Announcement
26 Mar '26
Capital Increase Completed
11 Mar '26
Bond Financing Update
27 Feb '26
Strategic Agreement
28 Jan '26
General Meeting Results
14 Nov '25
Interim Financial Report
31 Oct '25
Phase-3 Trial Launch
14 Oct '25
Funding Secured
15 Sep '25
Phase 3 Trial Announcement
11 Sep '25
New Clinical Trial
3 Sep '25
Obesity Trial Strategy
2 Sep '25
Regulatory Approval
28 Aug '25
Bond Debt Completion
6 Aug '25
2024 Financial Report
25 Jul '25
Strategic Partnership
18 Jul '25
Legal Victory
18 Jul '25
Conference Participation
17 Jul '25
Financial Results Released
11 Jul '25
BIO Convention Success
9 Jul '25
Delayed Accounts Release
3 Jul '25
Share Trading Halt
24 Jun '25
Event Participation
4 Jun '25
Financial Reporting Delay
2 Jun '25
Event Announcement
15 May '25
Financial Statement Delay
29 Apr '25
Mobility Restoration Target
22 Apr '25
Clinical Trial Launch
9 Apr '25
Private Placement Completed
31 Mar '25
Funding Success
26 Mar '25
Co-Development Agreement
20 Mar '25
License Negotiation
14 Jan '25
Funding Announcement
8 Jan '25
Share Suspension
6 Jan '25
Interim Financial Report
30 Sep '24
Partnership Announcement
22 Jul '24
FDA Approval News
11 Jul '24
COVA Study Results
1 Jul '24
General Meeting Approval
26 Jun '24
Exclusive Deal Announced
20 Jun '24
Contract Extension
20 Jun '24
Production Success
14 Jun '24
FDA Application Filed
11 Jun '24
General Meeting Notice
7 Jun '24
Obesity Study Announcement
14 May '24
Partner Search Strategy
29 Apr '24
ADS Transfer Report
25 Apr '24
ADR Ratio Change
19 Apr '24
New Advisory Board
18 Apr '24
Patent Application Filed
15 Apr '24
Financial Results Update
9 Apr '24
Clinical Study Launch
9 Apr '24
General Meeting Results
5 Apr '24
Press Release Update
22 Mar '24
Stock Split Announcement
18 Mar '24
Meeting Announcement
18 Mar '24
Event Participation Announced
12 Mar '24
Clinical Trial Results
8 Mar '24
Longevity Book Release
22 Feb '24
COVA Study Results
5 Jan '24
Funding Update
5 Jan '24
External Links:
SEC
On April 18, 2024, Biophytis S.A. announced the formation of a new Scientific Advisory Board for its phase 2 OBA clinical study focused on obesity.
AI Assistant
Close
BIOPHYTIS SA
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.